Opendata, web and dolomites
  1. home
  2. trasparenza
  3. open h2020
  4. irhom2 in ad

iRhom2 in AD SIGNED

iRhom2 in neuroinflammation and pathogenesis of Alzheimer’s Disease

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0
 Outcomes and results

 iRhom2 in AD project word cloud

Explore the words cloud of the iRhom2 in AD project. It provides you a very rough idea of what is the project "iRhom2 in AD" about.

protected    macrophages    risk    converting    cognitive    cell    cascade    inflammation    elderly    unless    cytokine    trafficking    plan    cure    accumulation    events    tace    additional    ad    dependent    triggered    mechanism    membrane    functional    protein    sepsis    dementia    pathology    plasma    rheumatoid    healthy    maturation    therapies    biochemical    cross    tnf    death    economical    candidates    disease    irhom2    traffic    implicated    foreseen    thereby    regulating    involve    worsen    validated    consequently    tangles    culminating    array    decline    alzheimer    socio    neurofibrillary    clients    inflammatory    treatment    though    form    guide    oligomers    rhomboid    primary    neuroinflammation    tumor    alpha    citizens    model    memory    ageing    signalling    mouse    assays    proteomic    syndrome    near    release    emerged    arthritis    enzyme    begins    neuron    garde    play    genetic    pro    progression    diseases    necrosis    found    regulate    line    dramatic    avant    mice    underlying    beta   

Project "iRhom2 in AD" data sheet

The following table provides information about the project.

Coordinator		 KLINIKUM RECHTS DER ISAR DER TECHNISCHEN UNIVERSITAT MUNCHEN 

Organization address
address: ISMANINGER STRASSE 22
city: MUENCHEN
postcode: 81675
website: http://www.med.tu.muenchen.de

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.
 Coordinator Country Germany [DE]
 Project website http://www.sciencedirect.com/science/article/pii/S0945053X16301329
 Total cost 159˙460 €
 EC max contribution 159˙460 € (100%)
 Programme 1. H2020-EU.1.3.2. (Nurturing excellence by means of cross-border and cross-sector mobility)
 Code Call H2020-MSCA-IF-2014
 Funding Scheme MSCA-IF-EF-ST
 Starting year 2015
 Duration (year-month-day) from 2015-12-01   to  2017-11-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    KLINIKUM RECHTS DER ISAR DER TECHNISCHEN UNIVERSITAT MUNCHEN DE (MUENCHEN) coordinator 159˙460.00

Map

 Project objective

Alzheimer’s disease (AD) is the most common form of dementia in the elderly, a syndrome characterized by loss of memory and cognitive decline. AD has a dramatic socio-economical impact that is foreseen to worsen in the near future unless a cure is found. The pathology is triggered by the accumulation of Aβ oligomers that begins a cascade culminating with the formation of neurofibrillary tangles within the neuron and cell death. Neuroinflammation is emerging to play a key role in this process and it has been associated with the progression of the disease. The rhomboid-like protein iRhom2 has been recently identified as a genetic risk factor for AD, even though the underlying mechanism remains to be characterized. iRhom2 recently emerged as a novel pro-inflammatory protein required to traffic TACE (tumor necrosis factor-α converting enzyme) towards the plasma membrane and guide its maturation, thereby regulating the release of TNFα, a cytokine implicated in several inflammatory diseases. Consequently, iRhom2-/- mice are protected from sepsis and rheumatoid arthritis, which involve TNFα-dependent inflammation. In addition, the concept is emerging that iRhom2 may regulate trafficking of additional clients other than TACE, thus controlling other signalling events in neuroinflammation. The main objective of this proposal is to characterize the role of iRhom2 in neuroinflammation and in the progression of AD. I plan to cross an AD mouse model with iRhom2-/- mice and evaluate role of iRhom2 in the progression of the disease. In addition, I will use avant-garde proteomic approaches to identify novel iRhom2 clients in primary macrophages. Candidates relevant in neuroinflammation and AD will be further validated using an array of biochemical and functional assays. From this research I aim to identify new targets to develop therapies for treatment of AD, in line with the objectives of H2020 Work Programme to promote healthy ageing of the EU citizens.

 Publications

year authors and title journal last update
List of publications.
2016 Simone D. Scilabra, Kazuhiro Yamamoto, Martina Pigoni, Kazuma Sakamoto, Stephan A. Müller, Alkmini Papadopoulou, Stefan F. Lichtenthaler, Linda Troeberg, Hideaki Nagase, Kenji Kadomatsu
Dissecting the interaction between tissue inhibitor of metalloproteinases-3 (TIMP-3) and low density lipoprotein receptor-related protein-1 (LRP-1): Development of a “TRAP” to increase levels of TIMP-3 in the tissue
published pages: , ISSN: 0945-053X, DOI: 10.1016/j.matbio.2016.07.004 		Matrix Biology 2019-06-14
2016 Stephan A. Müller, Simone D. Scilabra, Stefan F. Lichtenthaler
Proteomic Substrate Identification for Membrane Proteases in the Brain
published pages: , ISSN: 1662-5099, DOI: 10.3389/fnmol.2016.00096 		Frontiers in Molecular Neuroscience 9 2019-06-14

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "IRHOM2 IN AD" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "IRHOM2 IN AD" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.3.2.)

SingleCellAI (2019)

Deep-learning models of CRISPR-engineered cells define a rulebook of cellular transdifferentiation

Read More  

THIODIV (2020)

Exploring thioalkynes potential in gold catalysis with a divergent reactivity manifold

Read More  

DIFFER (2020)

Determinants of genetic diversity: Important Factors For Ecosystem Resilience

Read More